

Canada's Drug and Health Technology Agency

Report In Brief

Full Report

Summary



Scan or Click

Project Line: Health Technology Review

Published: August 2022

Project Number: RC1444-000

Guidelines for the Use of Virtual Care in Primary Care or Specialty Care Settings

Key Messages

Of the 5 evidence-based guidelines summarized in the report, 2 provide recommendations on rheumatology, 1 on stroke, 1 on oncology, and 1 on digital interventions for all areas of health, while none focus specifically on primary care. Three of the guidelines were developed in the context of the COVID-19 pandemic.

In general, the guidelines recommend virtual care as a complement to, not replacement for, in-person care, and indicate that it should only be implemented when adequate resources and personnel are available and patient privacy can be secured.

The recommendations are broad in scope and address various aspects of virtual care, including when to offer or discontinue virtual care, patient privacy, fees and reimbursement, and staff training. The guidelines include recommendations on the use of virtual care across multiple geographic locations, patient conditions, and virtual care modalities.

While the guidelines identify the convenience, flexibility, and potential time and cost savings associated with virtual care, there is limited evidence describing the potential barriers or limitations to its use, such as issues with internet access, technical support, and infrastructure, and the appropriate use of virtual care in underserved populations.

While all 5 guidelines were informed by a systematic literature search, when literature was lacking, some recommendations were developed using expert consensus only. The quality of the evidence supporting the recommendations was generally assessed as low, and the strength of the recommendations was not reported.

Context

Virtual care includes any interaction between patients and care providers that occurs remotely, using any form of communication or information technologies, and aims to facilitate or improve patient care. Included in this definition are telehealth services, audio conferencing (e.g., telephone), video conferencing (e.g., Zoom), secure messaging (e.g., text), and patient monitoring systems.

The COVID-19 pandemic accelerated the adoption of virtual health care across multiple specialties and settings across Canada.



Report In Brief

Contact



@cadth_acmts

requests@cadth.ca

Issue

The rapid adoption of virtual care necessitates a post-pandemic review of the virtual care literature. A review of the evidence may help inform strategies and policies, and aid in the development of standards for the effective implementation and continuation or discontinuation of virtual care.

The objective of this report is to summarize recent evidence-based guidelines regarding the appropriate use of virtual care for individuals using primary care or specialty care services.

Methods

A limited literature search was conducted of key resources, and titles and abstracts of the retrieved publications were reviewed and assessed for inclusion by a single reviewer. Full-text publications were evaluated for final article selection according to predetermined selection criteria specifying the population, intervention, comparator, outcomes, and study designs in scope for this report.

Results

The literature search identified 684 citations, 83 of which were deemed potentially relevant and underwent full-text review. Two potentially relevant publications were also retrieved from the grey literature search for full-text review. Of these publications, 5 evidence-based guidelines met the inclusion criteria and were included in the CADTH report. Additional references of potential interest, including guidelines that did not fully meet the selection criteria, were included in the appendix.

CADTH offers a range of evidence products and services. Contact us for more information on how we help meet decision-makers' needs.

Disclaimer

CADTH is a not-for-profit organization responsible for providing Canada's health care decision-makers with objective evidence to help make informed decisions about the optimal use of drugs and medical devices in our health care system.

CADTH receives funding from Canada's federal, provincial, and territorial governments, with the exception of Quebec.

This material is made available for informational purposes only and no representations or warranties are made with respect to its fitness for any particular purpose; this document should not be used as a substitute for professional medical advice or for the application of professional judgment in any decision-making process. Users may use this document at their own risk. The Canadian Agency for Drugs and Technologies in Health (CADTH) does not guarantee the accuracy, completeness, or currency of the contents of this document. CADTH is not responsible for any errors or omissions, or injury, loss, or damage arising from or relating to the use of this document and is not responsible for any third-party materials contained or referred to herein. Subject to the aforementioned limitations, the views expressed herein do not necessarily reflect the views of Health Canada, Canada's provincial or territorial governments, other CADTH funders, or any third-party supplier of information. This document is subject to copyright and other intellectual property rights and may only be used for non-commercial, personal use or private research and study.



